Anti-inflammatory reliever for asthma in children and teens
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests a new way to treat asthma flares in children and teens (ages 6–18) with mild-to-moderate asthma. It aims to see if a quick-relief anti-inflammatory medicine works better than current treatments to prevent severe attacks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 18 years old.
- You have asthma (either already diagnosed or newly diagnosed by a doctor).
- In the past year, you have had at least one asthma attack that needed steroids or a hospital visit.
- You can do a simple breathing test (spirometry or peak flow).
- You do not have active tuberculosis, heart problems, or uncontrolled diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study compares a new inhaler (QMF149: indacaterol plus mometasone) against budesonide to see which works better and is safe for children ages 6 to under 12 with asthma. You may be able to join if your child is already on a stable low-dose steroid inhaler and still has symptoms.
This study tests a new inhaler (PT027) against another inhaler (PT007) for teens aged 12 to 17 with asthma. It looks at how well the new inhaler works when used as needed, and if it is safe.
This study tests a new combination inhaler (budesonide/albuterol) against another asthma inhaler in adults whose asthma is not well controlled on their current medications. It aims to see if the new inhaler can reduce serious asthma attacks and improve symptoms.
This trial looks at why airflow is limited in people with moderate-to-severe persistent asthma who are already on stable treatment. It may help researchers better understand what drives breathing trouble and how to target it.
This Phase 3 trial compares a triple inhaler (FF/UMEC/VI) against the usual double inhaler (FF/VI) to help control asthma symptoms and breathing tests in teens ages 12–17. It also checks how safe and tolerable the treatments are over the study period.
This Phase 3 study tests whether an asthma care program with digital (phone-based) support helps people with severe asthma stay more stable and manage symptoms better. You may need to meet specific criteria for “severe, refractory” asthma and be willing to use a smartphone for monitoring and coaching.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.